Apremilast in dermatology: A review of literature-Reference-Cited by-同舟云学术

Apremilast in dermatology: A review of literature

Published:2020-09-27 Issue:6 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Nassim David¹^ORCID,Alajmi Ali²,Jfri Abdulhadi²,Pehr Kevin²^ORCID

Affiliation:

1. Faculty of Medicine McGill University Montreal Quebec Canada

2. Division of Dermatology McGill University, Jewish General Hospital Montreal Quebec Canada

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14261

Reference18 articles.

1. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

2. Celgene Corporation. Otezla (apremilast) [package insert]. U.S. Food and Drug Administration.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205437Orig1s007lbl.pdfRevisedJuly2019. Accessed August 21 2020.

3. Off-label studies on apremilast in dermatology: a review

4. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open‐label study;Paller AS;J Am Acad Dermatol,2019

5. Apremilast for treatment of recalcitrant aphthous stomatitis

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrent aphthous stomatitis in a child successfully treated with apremilast;Pediatric Dermatology;2024-09-05

2. Intradermal Injection of a Thermoresponsive Polymeric Dexamethasone Prodrug (ProGel-Dex) Ameliorate Dermatitis in an Imiquimod (IMQ)-Induced Psoriasis-like Mouse Model;Molecular Pharmaceutics;2024-09-03

3. Hailey-Hailey Disease Successfully Treated With Adalimumab: A Case Series;Cureus;2024-08-19

4. Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment;Medicinal Chemistry Research;2024-06-26

5. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation;Expert Opinion on Drug Safety;2024-05-06